TRAIL, Fas Ligand, TNF and TLR3 in Cancer - Resistance to Targeted Anti-Cancer Therapeutics - - Books - Springer International Publishing AG - 9783319860060 - August 12, 2018
In case cover and title do not match, the title is correct

TRAIL, Fas Ligand, TNF and TLR3 in Cancer - Resistance to Targeted Anti-Cancer Therapeutics Softcover reprint of the original 1st ed. 2017 edition

Price
$ 155.49
excl. VAT

Ordered from remote warehouse

Expected to be ready for shipping Jul 20 - 24

Our customers say:

14-day return policy in accordance with European consumer protection law
Top ranking on Trustpilot
Add to your iMusic wish list

Not rated yet

Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy.

317 pages, 35 Illustrations, color; 5 Illustrations, black and white; XIII, 317 p. 40 illus., 35 ill

Media Books     Paperback Book   (Book with soft cover and glued back)
Released August 12, 2018
ISBN13 9783319860060
Publishers Springer International Publishing AG
Pages 317
Dimensions 150 × 220 × 10 mm   ·   467 g
Language German  
Editor Micheau, Olivier

Mere med samme udgiver